Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 24, 2010
Outcomes of patients undergoing radical hysterectomy for cervical cancer of high-risk histological subtypes
Sonika Agarwal, Kathleen M Schmeler, Pedro T Ramirez, et al.
Scientific Reports
|
April 29, 2021
Extracellular vesicles derived from ascitic fluid enhance growth and migration of ovarian cancer cells
Aparna Mitra, Kyoko Yoshida-Court, Travis N Solley, et al.
Gynecologic Oncology
|
November 27, 2020
A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer
Anca Chelariu-Raicu, Alpa Nick, Renata Urban, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 30, 2020
Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer
Courtney D Bailey, Rebecca Previs, Bryan M Fellman, et al.
Gynecologic Oncology
|
February 8, 2021
Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study
Robert L Coleman, Wei Hu, Pamela Soliman, et al.
Plos One
|
January 6, 2023
Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer
Kyoko Yoshida-Court, Tatiana V Karpinets, Aparna Mitra, et al.
Plos One
|
November 22, 2024
Correction: Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer
Kyoko Yoshida-Court, Tatiana V Karpinets, Aparna Mitra, et al.
Scientific Reports
|
August 3, 2019
Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer
Stephen Shuford, Christine Wilhelm, Melissa Rayner, et al.
Med (New York, N.Y.)
|
August 16, 2024
Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial
Jeffrey A How, Minghao Dang, Sanghoon Lee, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 24, 2010
Outcomes of patients undergoing radical hysterectomy for cervical cancer of high-risk histological subtypes
Sonika Agarwal, Kathleen M Schmeler, Pedro T Ramirez, et al.
Scientific Reports
|
April 29, 2021
Extracellular vesicles derived from ascitic fluid enhance growth and migration of ovarian cancer cells
Aparna Mitra, Kyoko Yoshida-Court, Travis N Solley, et al.
Gynecologic Oncology
|
November 27, 2020
A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer
Anca Chelariu-Raicu, Alpa Nick, Renata Urban, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 30, 2020
Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer
Courtney D Bailey, Rebecca Previs, Bryan M Fellman, et al.
Gynecologic Oncology
|
February 8, 2021
Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study
Robert L Coleman, Wei Hu, Pamela Soliman, et al.
Plos One
|
January 6, 2023
Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer
Kyoko Yoshida-Court, Tatiana V Karpinets, Aparna Mitra, et al.
Plos One
|
November 22, 2024
Correction: Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer
Kyoko Yoshida-Court, Tatiana V Karpinets, Aparna Mitra, et al.
Scientific Reports
|
August 3, 2019
Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer
Stephen Shuford, Christine Wilhelm, Melissa Rayner, et al.
Med (New York, N.Y.)
|
August 16, 2024
Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial
Jeffrey A How, Minghao Dang, Sanghoon Lee, et al.
Page
of 1